CYP2B6 and OPRM1 gene variations predict methadone-related deaths

This source preferred by Wei-Jun Liang

Authors: Bunten, H., Liang, W.-J., Pounder, D., Seneviratne, C. and Osselton, D.M.

Journal: Addiction Biology

Volume: 16

Pages: 142-144

ISSN: 1355-6215

DOI: 10.1038/clpt.2010.127

The largest proportion of methadone-associated deaths occurs during the drug induction phase. We analysed methadone-related fatalities for gene variations linked with methadone action. A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. A significant correlation was also observed between post-mortem benzodiazepine concentrations and the OPRM1 A118G allele GA in methadone-related fatalities. Screening for these susceptibility variations prior to methadone prescription could assist in reducing the potential for serious adverse effects.

This data was imported from PubMed:

Authors: Bunten, H., Liang, W.-J., Pounder, D., Seneviratne, C. and Osselton, M.D.

Journal: Addict Biol

Volume: 16

Issue: 1

Pages: 142-144

eISSN: 1369-1600

The largest proportion of methadone-associated deaths occurs during the drug induction phase. We analysed methadone-related fatalities for gene variations linked with methadone action. A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. A significant correlation was also observed between post-mortem benzodiazepine concentrations and the OPRM1 A118G allele GA in methadone-related fatalities. Screening for these susceptibility variations prior to methadone prescription could assist in reducing the potential for serious adverse effects.

This data was imported from Scopus:

Authors: Bunten, H., Liang, W.J., Pounder, D., Seneviratne, C. and Osselton, M.D.

Journal: Addiction Biology

Volume: 16

Issue: 1

Pages: 142-144

eISSN: 1369-1600

ISSN: 1355-6215

DOI: 10.1111/j.1369-1600.2010.00274.x

The largest proportion of methadone-associated deaths occurs during the drug induction phase. We analysed methadone-related fatalities for gene variations linked with methadone action. A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. A significant correlation was also observed between post-mortem benzodiazepine concentrations and the OPRM1 A118G allele GA in methadone-related fatalities. Screening for these susceptibility variations prior to methadone prescription could assist in reducing the potential for serious adverse effects. © 2010 Society for the Study of Addiction.

This data was imported from Europe PubMed Central:

Authors: Bunten, H., Liang, W.J., Pounder, D., Seneviratne, C. and Osselton, M.D.

Journal: Addiction biology

Volume: 16

Issue: 1

Pages: 142-144

eISSN: 1369-1600

ISSN: 1355-6215

The largest proportion of methadone-associated deaths occurs during the drug induction phase. We analysed methadone-related fatalities for gene variations linked with methadone action. A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. A significant correlation was also observed between post-mortem benzodiazepine concentrations and the OPRM1 A118G allele GA in methadone-related fatalities. Screening for these susceptibility variations prior to methadone prescription could assist in reducing the potential for serious adverse effects.

The data on this page was last updated at 04:58 on April 25, 2019.